Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy
- First Online:
- 265 Downloads
Case reports have linked nonsteroidal antiinflammatory drugs (NSAIDs) to a variety of lesions in the small and large bowel including bleeding, protein loss, strictures, increased intestinal permeability, and NSAID enteropathy. We here review the use of wireless capsule endoscopy to quantitate and assess the nature of the small bowel damage caused by NSAIDs when taken short term and in patients on long-term NSAIDs and COX-2 inhibitors.
Forty healthy volunteers underwent a baseline capsule endoscopy. After taking diclofenac slow-release 75 mg twice a day for a total of 14 days, both investigations were repeated. A further 120 patients on long-term NSAIDs (more than 3 months) and 40 on COX-2 inhibitors underwent a capsule endoscopy study. Sixty healthy patients acted as controls. Small bowel damage was categorized and quantitated.
Short-term diclofenac: Capsule endoscopy demonstrated new pathology in 27 (68%) of subjects. The most common lesions were mucosal breaks, seen in 16 (40%), which were seen to be bleeding in 2 (5%). Long-term NSAIDs: The main pathology was related to mucosal breaks (29%); 3% had free luminal blood and 2% had strictures. The damage seen in 50% of patients on selective COX-2 inhibitors did not differ significantly (P < 0.5) from that seen with NSAIDs.
Capsule endoscopy demonstrates evidence of macroscopic injury to the small intestine, in up to 68% of volunteers, resulting from 2 weeks ingestion of slow-release diclofenac. Long-term use of NSAIDs and COX-2 inhibitors causes comparable small bowel damage (50%–68%).
Key wordsNSAID NSAID enteropathy COX-2 inhibitor capsule endoscopy
Unable to display preview. Download preview PDF.
- 1.Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc Lond 1763;53:195–200.Google Scholar
- 8.Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1992;266:12866–12872.Google Scholar
- 10.Rainsford K. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSAIDs. In: Rainsford KD, editor. Side effects of antiinflammatory drugs, vol 4. Dordrecht: Kluwer; 1997. 197–205.Google Scholar
- 26.Davies GR, Rampton DS. Relevance of intestinal bacteria, prostaglandins and pro-drug administration to NSAID induced increase in gut permeability (abstract). Gut 1991;32:A1224.Google Scholar
- 30.Shah AA, Thjodleifsson B, Murray FE, Sigthorsson G, Oddson E, Gudjonsson H, et al. A randomised, double blind, double dummy, crossover study of the effects of nimesulide and naproxen on the gastrointestinal tract and an in vivo assessment of their selectivity for cyclooxygenase 1 and 2. Gut 2001;48:339–348.PubMedCrossRefGoogle Scholar
- 35.Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Study. JAMA 2000;284:1247–1255.PubMedCrossRefGoogle Scholar
- 44.Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I. Long-term effects of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040–1045.PubMedCrossRefGoogle Scholar
- 46.Gomez-Rodriguez B, Caunedo-Alvarez A, Romero-Vasquez J, et al. NSAIDs erosive enteropathy assessed by capsule endoscopy: a prospective controlled trial (abstract). Gastroenterology 2004;126:A96.Google Scholar
- 48.Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665–674.PubMedCrossRefGoogle Scholar
- 49.Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527–532.PubMedCrossRefGoogle Scholar